GEN-MKT-18-7897-A
Dec 16, 2016 | Blogs, Forensic | 0 comments
There is a lot you can tell from a droplet of blood as it’s snapshot of what could be present in a body at any given moment. In the following application note, LC-MS/MS Screening of 64 New Psychoactive Substances Using Dried Blood Spots, researchers did just that as they used dried blood spots (DBS) opposed to the more invasive venipuncture technique to detect 64 psychoactive substances in samples.
To accomplish this research a highly sensitive QTRAP® LC-MS/MS was used in Multiple Reaction Monitoring (MRM) mode using the Scheduled MRM™ Algorithm. The importance of the method is that it can be expanded upon which is useful to government attempts at control the advent of new substances. When the European Monitoring System for Drugs and Addiction (EMCDDA) launched its Early Warning Program notification of new substances, for example, reported cases increased from 14 in 2008 to 98 in 2015.
As public awareness and government regulations like this become more profound, more accurate and less invasive testing methods are essential to keeping psychoactive substances off store shelves. In addition to sensitivity, the specimens can be easily stored, shipped, and maintained for future forensic testing.
Ultra‑low reporting limits, expanding target lists, and the constant risk of background contamination mean that even small missteps before injection can compromise data integrity. PFAS can be introduced at nearly every stage of prep, from sampling containers and PPE to SPE cartridges, filters, solvents, and lab consumables, making contamination control as critical as analyte recovery.
In monoclonal antibody (mAb) development, assessment of purity and integrity of the protein in question is critical. CE‑SDS is the gold standard assay and is routinely run from analytical development through QC and lot release. It’s trusted because it consistently delivers quantitative, size‑based insight into purity and fragmentation, and it fits naturally into regulated environments.
In drug discovery and development, Metabolite Identification (Met ID) plays a critical role in understanding biotransformation pathways, ensuring safety, and meeting regulatory requirements. Advanced mass spectrometry techniques have revolutionized this process, particularly through electron-based fragmentation methods such as Electron Activated Dissociation (EAD) and Electron Transfer Dissociation (ETD). While both techniques leverage electron interactions to generate informative fragment ions, they differ significantly in mechanism, performance, and suitability for Met ID workflows.
Posted by
You must be logged in to post a comment.
Share this post with your network